Loading...
•
Jul 03, 2021
Haemonetics Q1 2022 Earnings Report
Haemonetics reported first quarter fiscal 2022 results with increased guidance for vascular closure revenue and affirmed all other fiscal 2022 guidance, and expanded operational excellence program.
Key Takeaways
Haemonetics' first quarter fiscal 2022 performance showed a positive start to the year, driven by recovery across all businesses, especially Hospital, and initial Plasma Persona® rollouts. The company remains confident in strong end-market demand and anticipates full recovery from the pandemic by the end of the fiscal year. The revised Operational Excellence Program aims to enhance quality, service, and productivity, offsetting impacts from customer loss, the pandemic, and inflationary pressures.
First quarter fiscal 2022 revenue increased by 17% to $229 million.
Organic revenue growth was 16%.
Adjusted earnings per diluted share were $0.50.
The company is increasing guidance for Vascular Closure revenue and affirming all other fiscal 2022 guidance.
Haemonetics
Haemonetics
Haemonetics Revenue by Segment
Revenue by Segment
Plasma Revenue
CapyFin.comBlood Center Revenue
CapyFin.comHospital Revenue
CapyFin.com Forward Guidance
The Company affirmed its GAAP total revenue growth guidance of 13 – 18% and organic revenue growth guidance issued on May 13, 2021.
Positive Outlook
- Total revenue growth: 13-18%
- Plasma revenue growth: 15-25%
- Hospital revenue growth: 15-20%
- Adjusted operating margin: 19-20%
- Adjusted earnings per diluted share: $2.60 - $3.00
Challenges Ahead
- Blood Center revenue growth: (6-8%)
- Impact of currency fluctuation
- Strategic exits of product lines
- Acquisitions and divestitures
- Impact of the 53rd week in fiscal 2021
Revenue & Expenses
Visualization of income flow from segment revenue to net income